Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compound W Freeze Off

This article was originally published in The Tan Sheet

Executive Summary

At-home wart freezing treatment will be available in late August at food, drug, mass merchandise stores "in time for peak wart season," Medtech says Aug. 7. Pack of 12 foam applicators will carry SRPs of $25.99. Labeling instructs consumers to apply "simple swab-like applicator to the center of the wart for no more than 40 seconds. The applicator tip is cooled to about 55 degrees Celsius below zero." Warts should fall off within two weeks and the treated area should be replaced with new skin, the firm adds. Freeze Off will compete with Wartner's cryotherapy product, which launched this Spring (1"The Tan Sheet" April 28, 2003, p. 4)...

You may also be interested in...



Wartner Cryotherapy Product Looks To Freeze Wart Removal Competition

LDS Consumer Products' Wartner is the first OTC wart removal product featuring cryotherapy technology, according to the Cedar Rapids, Iowa-based firm

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel